Searchable abstracts of presentations at key conferences in endocrinology

ea0029p376 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

A patient with TSH-secreting pituitary macroadenoma, after previous thyroid ablation, successfully treated with long-acting octreotide formulation (octreotide-LAR) and transsphenoidal surgery

Gruszka A. , Kunert-Radek J.

Introduction: Thyrotropin (TSH)-secreting pituitary adenomas are rare (<1% of all pituitary tumors) and cause secondary hyperthyroidism.Case report: A 33-year old woman with type 1 diabetes mellitus presented in 2009 with palpitations. She had a past medical history of radioiodine therapy for thyrotoxicosis in 1998. After radioiodine treatment, she received an increasing daily dose of thyroxine (from 50 to 175 μg) because of her gradually rising...

ea0011p529 | Endocrine tumours and neoplasia | ECE2006

Endostatin and VEGF levels in serum of patients with pituitary tumors

Gruszka A , Kunert-Radek J , Pawlikowski M , Stepien H , Radek A

Endostatin, a cleaved fragment of collagen XVIII, is a potent endogenous angiogenesis inhibitor. Elevated serum endostatin levels have been recently reported in patients with various types of neoplasms. The purpose of our study was to evaluate serum concentrations of endostatin in patients harbouring various types of pituitary adenomas and to examine the relationship of serum endostatin levels to circulating vascular endothelial growth factor (VEGF) levels. Preoperative serum ...

ea0032p216 | Clinical case reports – Pituitary/Adrenal | ECE2013

Long-term treatment with octreotide in a patient with malignant pheochromocytoma: impact on survival and time to tumor progression

Gruszka Anna , Zieleniewski Wojciech , Kotecka-Blicharz Agnieszka , Jarzab Barbara , Kunert-Radek Jolanta

Introduction: Pheochromocytomas are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla. Approximately 10% of all pheochromocytomas are malignant. There is no effective therapy for malignant pheochromocytoma (MAL-PHEO) and the overall prognosis is poor.Case report: We report 22-year survival with MAL-PHEO in a patient treated with several surgeries, 131I-metaiodobenzylguanidine and, subsequently, with long-acting fo...